Ophthalmic manifestations of Heimler syndrome due to PEX6 mutations.

Nutsuchar Wangtiraumnuay  
*Wills Eye Hospital; Queen Sirikit National Institute of Child Health*

Waled Abed Alnabi  
*Wills Eye Hospital*

Mai Tsukikawa  
*Thomas Jefferson University, mai.tsukikawa@jefferson.edu*

Avrey Thau  
*Wills Eye Hospital; Thomas Jefferson University, athau@willseye.org*

Jenina Capasso  
*Wills Eye Hospital, jxc246@jefferson.edu*

*See next page for additional authors*

Let us know how access to this document benefits you

Follow this and additional works at: [http://jdc.jefferson.edu/willsfp](http://jdc.jefferson.edu/willsfp)

Part of the [Ophthalmology Commons](http://jdc.jefferson.edu/willsfp)

Recommended Citation

Wangtiraumnuay, Nutsuchar; Alnabi, Waled Abed; Tsukikawa, Mai; Thau, Avrey; Capasso, Jenina; Sharony, Reuven; Inglehearn, Chris F.; and Levin, Alex V., "Ophthalmic manifestations of Heimler syndrome due to PEX6 mutations." (2018). *Wills Eye Hospital Papers*. Paper 83.  
[http://jdc.jefferson.edu/willsfp/83](http://jdc.jefferson.edu/willsfp/83)
Ophthalmic Manifestations of Heimler Syndrome due to PEX6 Mutations

Nutsuchar Wangtiraumnuay, MD,1,2 Waleed Abed Alnabi, MD,1 Mai Tsukikawa,3 Avrey Thau, MD,3 Jenina Capasso, LCGC,1 Reuven Sharony, MD,4 Chris F Inglehearn, PhD,5 Alex V Levin, MD, MHSc,1,3

1 Wills Eye Hospital, Philadelphia, Pennsylvania, USA.

2 Department of Ophthalmology; Queen Sirikit National Institute of Child Health, Bangkok, Thailand.

3 Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania; USA.

4 The Genetic Institute and Obstetrics and Gynecology Department, Meir Medical Center affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Kfar Saba, Israel.

5 Leeds Institute of Biomedical and Clinical Sciences, St. James's University Hospital, University of Leeds, Leeds LS9 7TF, UK.

Address for correspondence:
Alex V. Levin, MD, MHSc
Chief, Pediatric Ophthalmology and Ocular Genetics
Wills Eye Hospital, Suite 1210, 840 Walnut Street, Philadelphia, PA 19107-5109
Phone: 215-928-3418; Fax: 215-928-3983, Email: alevin@willseye.org

Running head: Macular dystrophy in Heimler Syndrome
Abstract

**Background/Aims:** Pigmentary retinal dystrophy and macular dystrophy have been previously reported in Heimler syndrome due to mutations in *PEX1*. Here we reported the ocular manifestations in Heimler syndrome due to mutations in *PEX6*.

**Materials and methods:** Medical records were reviewed to identify patient demographics, ophthalmic and systemic findings, and results of diagnostic testing including whole genome sequencing.

**Results:** Patient 1 is 12-year-old boy with a novel mutation c.275T>G (p.Val92Gly) and known mutation c.1802G>A (p.Arg601Gln) in *PEX6*. Patient 2 is a 7 year-old girl with the same known c.1802G>A (p.Arg601Gln) mutation and another novel missense mutation c.296G>T (p.Arg99Leu). Both patients exhibited a pigmentary retinopathy. Visual acuity in patient 1 was 20/80 and 20/25 following treatment of intraretinal cystoid spaces with carbonic anhydrase inhibitors, while patient 2 had visual acuity of 20/20 in both eyes without intraretinal cysts. Fundus autofluorescence showed a multitude of hyperfluorescent deposits in the paramacular area of both eyes. OCTs revealed significant depletion of photoreceptors in both patients and macular intraretinal cystoid spaces in one patient. Full field electroretinograms showed normal or abnormal photopic but normal scotopic responses. Multifocal electroretinograms were abnormal.

**Conclusions:** Heimler syndrome due to biallelic *PEX6* mutations demonstrates a macular dystrophy with characteristic fundus autofluorescence and may be complicated by intraretinal cystoid spaces.

**Keyword:** Heimler syndrome, *PEX6*, Macular dystrophy
Introduction

Heimler syndrome was first described by Heimler et al. in 1991. This autosomal recessive disorder has since been shown to be caused by biallelic mutations in PEX1 or PEX6. The cardinal features include acquired sensorineural hearing loss (SNHL), amelogenesis imperfecta of the teeth, retinal dystrophy and abnormal nails (punctate leukonychia or Beau’s lines).

Pigmentary retinal dystrophy and macular dystrophy have been previously reported in Heimler syndrome. These prior reports primarily describe the ocular manifestations of Heimler syndrome due to mutations in PEX1. We previously reported a brief description of the ocular manifestations of one patient with Heimler syndrome due to mutations in PEX6, and now provide more detail about that patient and another.

Materials and methods:

This study is an observational, retrospective study. The medical records of all patients with the clinical diagnosis of Heimler syndrome seen at the Ocular Genetics Clinic at Wills Eye Hospital from 2010 to 2016 were reviewed retrospectively. IRB/Ethics Committee ruled that approval was not required for this study. Two patients with the diagnosis of Heimler syndrome were identified. Their medical records were reviewed to identify patient demographics, ophthalmic and systemic findings, and results of other testing. The patients had whole exome sequencing performed at the Leeds Institute of Biomedical and Clinical Sciences (Leeds, UK). Testing methodology, genotype results and systemic phenotypes of both patients have been previously reported by Smith et al.
Both patients had a full ophthalmic examination by an ocular genetic specialist (AVL), including visual acuity, slit lamp and dilated fundus examination. Fundus autofluorescence (FAF) images, Goldmann visual fields and spectral domain-optical coherence tomography (SD-OCT) images were obtained. Full-field electroretinogram (ffERG) and multifocal electroretinogram (mfERG) were performed in accordance with the International Society of Clinical Electrophysiology and Vision standards.6

Results:

The BCVA, anterior segment examination, fundus examination, color vision and cycloplegic refraction for each patient are summarized in Table 1.

Case 1: This 12-year-old boy with congenital high frequency sensorineural hearing loss (SNHL) was the product of an uncomplicated pregnancy. Family history was unremarkable. Initially he presented with delayed speech which resulted in the diagnosis of SNHL at 18 months old, requiring hearing aids. He had positional posterior plagiocephaly, toe walking and learning disability with normal IQ testing and a normal brain MRI scan. Hyperpigmentation was observed along the lines of Blaschko on the left shoulder and arm, together with Beau's lines on both great toe nails (Figure1A), and amelogenesis imperfecta on the secondary teeth. Between 5 and 9 years of age, he had occlusion therapy for strabismic amblyopia of his right eye. Pigmentary retinal changes were noted at 3 years old. He had no nyctalopia or evidence of constricted visual fields. He had continued ophthalmic follow up and subsequently was referred to Wills Eye Hospital at age 12 for further evaluation.

Fundus autofluorescence (FAF) and optical coherence tomography (OCT) images are shown in Figure 2. The patient did not have intravenous fluorescein angiography testing.
The mfERG showed decreased central and paracentral amplitudes and delayed implicit time in both eyes (Figure 2). The ffERG waveforms were normal in response to scotopic and combined flash stimuli in both eyes, but showed decreased amplitude and delayed implicit time of the A- and B-wave in response to single flash photopic stimuli and 30 Hz flicker (Figure 2). Goldmann visual fields were normal in both eyes. The patient was treated with topical and oral acetazolamide for his intraretinal cystoid spaces and had improvement from 20/125 to 20/80 in the right eye and 20/40 to 20/25 in the left eye. After 5 years of follow up, the patient’s visual acuity was stable with oral acetazolamide as his only medication.

Karyotype revealed a normal male karyotype. A single nucleotide polymorphism (SNP) microarray (Quest Diagnostic Nichols Institute, Chantilly, Virginia) found a 146-kb deletion at 5q21.3 and 466 kb duplication at 1p32.1p31.3, both of which were maternally inherited. Maternal eye examination status post LASIK surgery showed a mildly shallow anterior chamber, bilateral cortical lens flecks, a normal fundus and a normal appearance with optical coherence tomography. Paternal eye examination showed high myopic astigmatism with bilateral cortical lens flecks and a normal fundus. Sequencing of the exons and flanking intronic areas of CNNM4 and NR2E3 (Casey Eye Institute, Portland, OR, USA) detected no abnormal findings and no deletions or duplications were found. The OtoGenome hearing loss panel of 71 genes (Laboratory for Molecular Medicine, Cambridge, MA, USA) was normal. Whole exome sequencing revealed compound heterozygosity in the PEX6 gene: a novel mutation c.275T>G (p.Val92Gly) and known mutation c.1802G>A (p.Arg601Gln). The novel mutation affects a region of the gene that is conserved in mammalian species. Both SIFT and Mutation-Taster programs predict pathogenicity. PolyPhen-2 predicts the change to be probably damaging. The known mutation c.1802G>A
Macular Dystrophy in Heimler Syndrome

is maternally inherited and the novel mutation c.275T>G is paternally inherited. This patient is Family2 in Smith et al.5

Case 2: This 7-year-old girl is the product of an uncomplicated pregnancy born to a 33-year-old mother, who has a periauricular skin tag, hypoglossal duct surgery and hypothyroidism, and a healthy 36-year-old father. There is no known consanguinity. Family history is otherwise unremarkable except for the patient’s brother who had hydronephrosis requiring bilateral ureteral implantation surgery. Our patient had a normal voiding cystourethrogram (VCUG) in the neonatal period.

She was entirely well until 3 years old when she was diagnosed with bilateral sensorineural hearing loss, requiring hearing aids, with normal speech (Figure 1B). She had amelogenesis imperfecta of her primary and secondary molars (Figure 1C). Nails were normal. She had a small cutaneous capillary hemangioma on her right lower chest. Between 3 and 5 years old, she was treated for amblyopia in her left eye with patching and glasses. At 7 years old, retinal pigmentary changes were found. Her night vision was normal, but she sometimes had photophobia. She was referred to Wills Eye Hospital for further evaluation.

FAF and OCT images are shown in Figure 3. FfERG waveforms were normal in response to scotopic stimuli, photopic stimuli, combined flash and 30Hz flicker (Figure 3). MfERG waveforms were decreased in amplitude paracentrally in response to pseudorandom honeycomb pattern stimuli in both eyes (Figure 3). The responses were slightly better centrally and peripherally. Goldmann visual fields were normal.

SNP Microarray analysis (Quest Diagnostic Nichols Institute, Chantilly, VA, USA) was normal. OtoChip screening (Molecular Otolaryngology and Renal Research Laboratories, IA,
Macular Dystrophy in Heimler Syndrome

USA) was negative. Sequencing of the exons and flanking intronic areas of CNNM4 (Casey Eye Institute, Portland, OR, USA) was normal and no deletions or duplications were found. Whole exome sequencing revealed compound heterozygosity for mutations in PEX6, these being the known mutation\(^2\) c.1802G>A (p.Arg601Gln) mutation and a novel missense mutation c.296G>T (p.Arg99Leu). The novel mutation affects a region of the gene that is conserved in mammalian species.\(^5\) The Mutation-Taster program predicts pathogenicity. PolyPhen-2 predicts the change to be probably damaging while SIFT predicts this variation to be non-deleterious. The known mutation c.1802G>A is maternally inherited and the novel mutation c.296G>T is paternally inherited. This patient is Family 3 from Smith et al.\(^5\)

**Discussion:**

The ocular manifestations of Heimler syndrome were first reported by Lima et al., who characterized the macular dystrophy in a 29-year-old female, later shown to be compound heterozygous for mutations in PEX1\(^4\). Key findings included decreased visual acuity with “salt and pepper” fundus, hyper and hypoautofluorescent dots in the posterior pole and periphery of the retina, loss of the “inner/outer segment boundary” and RPE thinning in OCT with normal ffERG. Ratbi et al. described “retinal pigmentation”, macular dystrophy and visual impairment, and more recently, retinitis pigmentosa. Smith et al. described 6 families with Heimler syndrome. Five had initially been misdiagnosed as Usher syndrome. The ocular findings were briefly described in one patient with PEX6 mutations who is our patient 2. Families 2 and 3 described by Smith et al. are our patients 1 and 2, respectively.\(^2\) We herein report further detailed characterization of their ocular phenotype. To the best of our knowledge, our cases represent the first report of detailed characterization of the ocular findings in Heimler syndrome due to mutations in PEX6.
Macular Dystrophy in Heimler Syndrome

Heimler syndrome exhibits phenotypic variability. SNHL can be unilateral or bilateral and nails can be normal.\(^7\)\(^-\)\(^8\) Amelogenesis imperfecta usually manifests in secondary teeth, with posterior (premolar and molar) teeth more severely affected than anterior (incisor) teeth. Amelogenesis imperfecta is also seen in Jalili syndrome,\(^9\) hyperbilirubinemia, premature birth, hypoparathyroidism, viral infections and in response to excessive fluoride or tetracycline. Jalili syndrome is associated with cone-rod dystrophy and is therefore relevant to the differential diagnosis in our patient, although our patient did not have mutations in \(CNNM4\).

Our case 1 had typical findings of Heimler syndrome including SNHL, amelogenesis imperfecta and abnormal nails. He also had posterior plagiocephaly, toe walking and learning disability. Posterior plagiocephaly without lambdoidal synostosis is frequent in the general population when positional and is likely unrelated. SNP microarray revealed a 146-kb deletion at 15q21.3 and 466 kb duplication at 1p32.1p31.3, both inherited from his unaffected mother, suggesting that these copy number variations are likely benign. Sequencing of \(CNNM4\) was negative and screening with the OtoGenome hearing loss panel was normal. Delayed development with amelogenesis imperfecta had been reported with mutations in \(PEX6\).\(^5\) Patient 2 also had findings typical of Heimler syndrome, including SNHL and amelogenesis imperfecta. SNP microarray analysis, \(CNNM4\) sequencing and deletion/duplication analysis were normal. Whole exome sequencing revealed \(PEX6\) pathogenic sequence changes in both patients.\(^5\)

The discovery that hypomorphic \(PEX1\) and \(PEX6\) mutations cause Heimler syndrome\(^2\)\(^-\)\(^5\) identifies the condition as a peroxisomal disorder. One study suggests that mutations in \(PEX1\) are more common\(^2\) while another found \(PEX6\) mutations to be more
common. Other peroxisomal disorders include Zellweger syndrome, neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD) and chondrodysplasia punctata. Mutations in PEX1 and PEX6 may also result in a form of Zellweger syndrome, which is characterized by craniofacial abnormalities, neurologic dysfunction, and liver dysfunction. Ocular manifestations were not specifically described. In other forms of Zellweger syndrome, some of which were not molecularly defined, ocular findings include nystagmus, cloudy corneas, glaucoma, cataract, retinal dystrophy with extinguished ERG, macular intraretinal cystoid spaces and optic atrophy. Our patients, and those reported by Ratbi and Lima, had a milder form of retinal dystrophy compared to other patients with Zellweger syndrome.

The peroxisome is a cytoplasmic organelle. Its main function is the breakdown of very long chain fatty acids through beta-oxidation. The PEX1 and PEX6 proteins bind with adenosine triphosphate (ATP) to form a heterohexameric ATPase which is associated with various cellular activities that fuel essential protein transport across peroxisomal membranes, the final steps of peroxisomal matrix-protein import. PEX1 and PEX6 are expressed in the retina, especially in photoreceptors. Abnormal PEX6 and PEX1 proteins result in abnormal peroxisomal function, leading to the accumulation of very long chain fatty acids. Histopathology of other peroxisomal disorders shows accumulation of characteristic bileaflet fatty acid inclusions in photoreceptors, RPE and pigment laden macrophages. Fatty acid accumulation may create the lipofuscin-like substances which appear as hyperfluorescent flecks seen on FAF in our patients.

Our patients showed similarities to and differences from the ocular manifestations resulting from the mutations in PEX1. Visual acuity in our case 1 and Lima’s patients showed
Macular Dystrophy in Heimler Syndrome

asymmetrical visual loss, while patient 2 had BCVA of 20/20 in both eyes. The decreased vision in the right eye in patient 1 may be attributed, in part, to strabismic amblyopia or the macular cysts, or a combination of both. Anterior segments were normal, except our case 1 which had mild cortical cataract, which has not previously been reported in Heimler syndrome. OCT revealed intraretinal cystoid spaces in the outer plexiform layer in our case 1, Lima’s patient and Ratbi’s patient. We found mottling of the macular RPE and hyperfluorescent deposits with central macular sparing by FAF in our patients as also reported by Lima et al.

FfERGs were normal in patient 2 and showed mild photopic abnormalities in patient 1 which differs from Ratbi’s patient, who harbored PEX1 mutations and showed abnormal scotopic and photopic responses. The mfERG in our patients are abnormal, consistent with the observed macular dystrophy as also reported by Lima. The patient of Lima et al. was more severely affected. This may be due to the patient’s older age (29 years old) or may perhaps suggest a more potent effect of PEX1 mutations. The patient of Ratbi et al., had a retinitis pigmentosa phenotype not seen in our patients. We had personal communication with the physician of the patients from family 5 in Smith et al. A pair of siblings with Heimler syndrome who harbored PEX6 mutation, they had a retinitis pigmentosa phenotype with intraretinal cystoid spaces similar to Ratbi’s patient. Our ERG findings suggest a predominant effect of the PEX6 mutation on the cone system which may be due to fatty acid deposition in macula as shown by FAF.

The intraretinal cystoid spaces in our case 1 may or may not represent cystoid macular edema. IVFA had not been done to distinguish these possibilities. The patient was treated with topical and oral acetazolamide and had some improvement of visual acuity and
remained stable after 5 years follow-up with oral acetazolamide as his maintenance medication. The patient reported by Lima et al. showed non-leaking intraretinal cystoid spaces by IVFA. Treatment details were not provided. Ratbi’s patient, who had been treated with oral acetazolamide, intravitreal triamcinolone acetonide and intravitreal ranibizumab, did not show resolution of intraretinal cystoid spaces. The OCTs of our patients were variable and not particularly correlated with their vision as previously reported.25

In conclusion, we report the ocular findings of Heimler syndrome due to PEX6 mutations. Ophthalmic examination can be helpful in this disorder, showing a characteristic pattern on FAF along with changes on OCT, ffERG, and mfERG. Patients with intraretinal cystoid spaces may benefit from carbonic anhydrase therapy. Long term follow-up is required to better understand the ocular prognosis of this disease. Heimler syndrome, and ocular examination with diagnostic testing, should be considered in patients with SNHL or amelogenesis imperfecta.

Declaration of interest

This work was supported in part by the Foerderer Fund (AVL), The Robison D. Harley, MD Endowed Chair in Pediatric Ophthalmology and Ocular Genetics (AVL) and RP Fighting Blindness and Fight For Sight (the RP Genome Project GR586 - CI). Neither the sponsor nor the funding organizations had a role in the design or conduct of this research.
Macular Dystrophy in Heimler Syndrome

References


Macular Dystrophy in Heimler Syndrome


